Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Badar T, et al. Am J Hematol. 2016 Aug;91(8):800-5. doi: 10.1002/ajh.24415. Epub 2016 Jun 25. Am J Hematol. 2016. PMID: 27169385 Free PMC article. Clinical Trial.
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Badar T, et al. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213. doi: 10.1038/s41409-018-0178-5. Epub 2018 Apr 20. Bone Marrow Transplant. 2018. PMID: 29679076 No abstract available.
Ibrutinib: a paradigm shift in management of CLL.
Badar T, Burger JA, Wierda WG, O'Brien S. Badar T, et al. Expert Rev Hematol. 2014 Dec;7(6):705-17. doi: 10.1586/17474086.2014.977862. Expert Rev Hematol. 2014. PMID: 25387837 Free PMC article. Review.
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Badar T, et al. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):433-438.e2. doi: 10.1016/j.clml.2015.02.018. Epub 2015 Feb 19. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25795639 Free PMC article. Clinical Trial.
106 results